Moleculin Biotech Completes NASDAQ IPO Raising $9.24M
Summary
Moleculin Biotech, Inc., (NASDAQ: MBRX), a Houston, TX-based preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D.The net proceeds of the offering will help finance a Phase II clinical trial for Annamycin, an anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML.Other uses of the IPO funding include, license maintenance and IP prosecution costs, research, and general working capital purposes.Led by Founder, Chairman, CEO, and Business Advisory Board Member Walter Klemp, Moleculin is advancing Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML.It also has two active pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
